April 26, 2012
1 min read
Save

Gut-directed hypnotherapy remained effective for children

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The benefits of gut-directed hypnotherapy for pediatric patients with functional abdominal pain or irritable bowel syndrome are long lasting, according to recent research from a follow-up study.

The researchers previously had conducted a randomized, controlled trial of 52 participants demonstrating that gut-directed hypnotherapy (HT) for children (n=27) with functional abdominal pain (FAP) or irritable bowel syndrome (IBS) was highly effective, and 85% were symptom-free 1 year after treatment. The HT patients were compared with 25 children who were administered standard medical treatment in combination with supportive therapy (SMT). At 1-year follow-up, 25% of the SMT group was symptom-free.

Children assessed their pain intensity and frequency of pain by completing a weeklong standardized abdominal pain diary with scoring criteria. Clinical remission was defined as >80% improvement in pain intensity and pain frequency scores compared with baseline.

In the follow-up study, after a mean duration of 4.8 years and a mean age of 17.8 years, researchers said 68% of the HT patients (n=18) compared with 20% of the SMT group (n=4) remained in clinical remission (P=.005). Pain intensity and pain frequency scores were 7.3 and 7.1, respectively, for the SMT group (P<.01), while the HT patients were significantly lower at 2.8 and 2.3, respectively. Three SMT children from the initial study did not participate in the follow-up.

“This follow-up study clearly shows that beneficial effects of gut-directed HT sustain over a period of 5 years in children with FAP or IBS,” researchers wrote. “Gut-directed HT can be considered as a highly valuable therapeutic option for children with long-lasting complaints of IBS or FAP.”

Researchers said a larger randomized, controlled trial sample should be conducted in the future to confirm their long-term results.